MORGAN STANLEY - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$327,823
+52.7%
277,816
+82.5%
0.00%
Q2 2023$214,643
-53.3%
152,229
-50.3%
0.00%
Q1 2023$459,180
+197.8%
306,120
+132.3%
0.00%
Q4 2022$154,197
+120.3%
131,793
+110.7%
0.00%
Q3 2022$70,000
-65.5%
62,562
-51.5%
0.00%
Q2 2022$203,000
-46.0%
128,905
-47.2%
0.00%
Q1 2022$376,000
-71.0%
244,155
-53.8%
0.00%
Q4 2021$1,295,000
+309.8%
528,557
+321.7%
0.00%
Q3 2021$316,000
-13.9%
125,343
-2.7%
0.00%
Q2 2021$367,000
+41.7%
128,762
+16.5%
0.00%
Q1 2021$259,000
+13.6%
110,527
-14.8%
0.00%
Q4 2020$228,000
+356.0%
129,670
+142.9%
0.00%
Q3 2020$50,000
-31.5%
53,383
-36.9%
0.00%
Q2 2020$73,000
+52.1%
84,546
+44.9%
0.00%
Q1 2020$48,000
-72.6%
58,348
-70.4%
0.00%
Q4 2019$175,000
+130.3%
197,324
+152.9%
0.00%
Q3 2019$76,00078,0220.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders